Intake Periods (Weeks) | Change (%) | |||
---|---|---|---|---|
0 | 8 | |||
AST (IU/L) | Control | 50.4 ± 26.7 | 35.2 ± 12.3 | 88.8 ± 9.9 |
LAFEW 6 g | 21.9 ± 1.9 | 22.1 ± 2.4 | 101 ± 5.4 | |
LAFEW 8 g | 31.3 ± 6.0 | 28.7 ± 4.4 | 98.2 ± 12.2 | |
ALT (IU/L) | Control | 52.2 ± 28.2 | 45.4 ± 21.7 | 95.5 ± 6.2 |
LAFEW 6 g | 22.0 ± 2.8 | 23.4 ± 3.7 | 105 ± 7.2 | |
LAFEW 8 g | 49.0 ± 12.9 | 39.0 ± 10.5 | 94.3 ± 21.4 | |
γ-GTP (IU/L) | Control | 72.6 ± 33.0 | 74.6 ± 35.5 | 105 ± 9.9 |
LAFEW 6 g | 70.6 ± 21.3 | 70.9 ± 24.4 | 96.7 ± 5.8 | |
LAFEW 8 g | 37.8 ± 7.3 | 33.7 ± 7.3 | 86.8 ± 5.4 | |
BUN (mg/dL) | Control | 13.0 ± 1.3 | 14.2 ± 0.9 | 111 ± 8.2 |
LAFEW 6 g | 12.5 ± 1.1 | 11.2 ± 0.7# | 92.5 ± 7.8 | |
LAFEW 8 g | 12.8 ± 0.5 | 11.8 ± 0.7 | 91.9 ± 4.3 | |
Cr (mg/dL) | Control | 0.748 ± 0.042 | 0.752 ± 0.039 | 101 ± 2 |
LAFEW 6 g | 0.779 ± 0.029 | 0.836 ± 0.030* | 108 ± 3 | |
LAFEW 8 g | 0.798 ± 0.032 | 0.823 ± 0.024 | 104 ± 3 | |
UA (mg/dL) | Control | 6.34 ± 0.15 | 6.16 ± 0.37 | 97.7 ± 7.4 |
LAFEW 6 g | 5.96 ± 0.31 | 5.83 ± 0.30 | 98.4 ± 4.0 | |
LAFEW 8 g | 6.12 ± 0.47 | 5.95 ± 0.46 | 98.1 ± 5.6 |